369010login-checkInvestigational Oral CKD-Anemia Agent Effective, Safe |
“The investigational hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) daprodustat was safe and as effective as erythropoiesis-stimulating agents (ESAs) for anemia, according to the phase III ASCEND program.
In the first of the two ASCEND trials looking at patients with chronic kidney disease undergoing dialysis, patients treated with oral daprodustat had a mean change in hemoglobin level of 0.28±0.02 g/dL from baseline to weeks 28 through 52, reported Ajay Singh, MBBS, MBA, of Brigham and Women’s Hospital in Boston and chair of the ASCEND program’s Executive Steering Committee, and colleagues.”
Read more, here.
369010login-checkInvestigational Oral CKD-Anemia Agent Effective, Safe |